Qurient Co., Ltd.

10 clinical trials · Sponsor

Record	Firm	Date
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors (NCT05438420)	Qurient Co., Ltd.	2023-01-12
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors (NCT05394103)	Qurient Co., Ltd.	2022-08-30
A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients (NCT04847583)	Qurient Co., Ltd.	2021-07-29
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor (NCT04648254)	Qurient Co., Ltd.	2020-11-18
A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203) (NCT03563599)	Qurient Co., Ltd.	2018-07-23
Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients (NCT03571620)	Qurient Co., Ltd.	2018-06-21

Every clearance here is in the API, with alerts when new ones post.